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ABSTRACT 
 
Background: Sorafenib, the first oral anti-angiogenic multikinase inhibitor, is primarily used in 
the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.  
Common toxicities experienced by patients treated with sorafenib include diarrhea, hand-foot 
skin reaction, hypertension, and rash.  These toxicities limit sorafenib’s use and affect adherence 
to treatment, reducing sorafenib efficacy.  The purpose of this study was to identify, for the first 
time, genetic markers of sorafenib toxicity in order to optimize its efficacy and minimize 
toxicity.  No novel genetic biomarkers are currently available to identify patients at risk of 
sorafenib-induced toxicity.  
 
Methods: Metastatic renal cell carcinoma (mRCC) patients (N=153) treated with sorafenib, as 
part of the TARGET study, were genotyped for common germline genetic variants in 50 
candidate genes.  Associations between 5846 variants and sorafenib-induced Grade 2-4 toxicities 
were analyzed.  Patients treated for less than or equal to 28 days were excluded from the 
analysis.  Toxicities analyzed included diarrhea, hypertension, hand-foot skin reaction, and/or 
rash or desquamation.  For each toxicity, the worst grade event for each patient was used in the 
analysis.  After linkage disequilibrium-based pruning, 685 variants were utilized in case/control 
association testing for analysis of each toxicity via a chi-squared test to compare allele 
frequencies between cases (patients with toxicity) and controls (patients without toxicity). 
 
Results: Of the 153 patients, 28 (18 percent) experienced Grade ≥ 2 diarrhea.  The A allele of 
rs917881 (G>A), an intronic variant (17 percent allele frequency) in the epidermal growth factor 
receptor (EGFR) gene, was associated with an increased risk of Grade ≥ 2 diarrhea (P=0.00006; 
P=0.04 after Bonferroni’s correction; odds ratio 3.6).  The frequency of Grade ≥ 2 diarrhea was 
50 percent (3/6) in AA, 33 percent (15/45) in AG, and 10 percent (10/102) in GG patients.  The 
frequency of Grade 3 diarrhea was 8 percent (4/51) in patients with the A allele (AA+AG) versus 
2 percent (2/102) in patients with the GG genotype.  No other variants were significantly 
associated with sorafenib toxicity after Bonferroni correction. 
 
Conclusion: To our knowledge, this is the first reported study of a genetic basis of sorafenib 
toxicity.  rs917881 is a common intronic variant in EGFR. RAF kinase, a critical component of 
the EGFR signaling pathway, is a known target of sorafenib.  Patients with the rs917881 A allele 
treated with sorafenib may be at an increased risk for diarrhea as a result of decreased EGFR 
expression potentiated by sorafenib-induced inhibition of the RAF/MEK/ERK pathway, which 
regulates chloride secretion on colonic epithelial cells.  Replication analyses in additional patient 




The primary aim of pharmacogenetics is to understand how genetic variants influence 
drug efficacy and toxicity.
1
  Specifically in the field of oncology, the goal of pharmacogenetics 
serves to optimize treatment in order to improve survival from disease and to mitigate toxicities 
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related to drug therapies.  Identification of pharmacogenetic variants which associate with drug 
efficacy or toxicity could impact clinician treatment decisions and improve patient outcomes. 
Kidney cancer, a disease of the middle-aged and elderly, is among the ten most 
frequently diagnosed cancers in males and females in the United States.  Despite advancements 
in early detection techniques, approximately one-third of patients present with regional or distant 
metastases.  Current overall five-year survival rates are 74% and decrease to 53% among patients 
with locoregional (stage III) disease and to 8% among patients with metastatic (stage IV) 
disease.
2
  Renal cell carcinoma (RCC), the most common form of kidney cancer, accounts for 90 
percent of all malignancies that arise in the kidney and renal pelvis.  Metastatic RCC (mRCC) 
responds poorly to standard cytotoxic chemotherapy, and interferon alfa, the previous standard of 
care, has been replaced by oral targeted therapies – including vascular endothelial growth factor 
(VEGF) inhibitors and mechanistic target of rapamycin (mTOR) inhibitors – which have 
demonstrated higher response rates, longer progression-free survival (PFS), or both.
2 
Sorafenib (Nexavar®) was approved by the Food and Drug Administration (FDA) in 
2005 as the first oral anti-angiogenic multikinase inhibitor for the treatment of advanced and 
mRCC;
3
 it is currently used in clinical practice in mRCC as a second line treatment option after 
sunitinib or pazopanib, or as a subsequent treatment option.
2
  Sorafenib can be used as a first line 
treatment option in mRCC in selected patients.
4  
Since its approval in mRCC, sorafenib has 
emerged as a first line treatment option in unresectable hepatocellular carcinoma (HCC) and in 
locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) refractory to 
radioactive iodine treatment.
3,5 
Sorafenib exerts broad spectrum antitumor activity with targets including receptor 
tyrosine kinases involved in tumor progression and angiogenesis; it blocks the activation of 
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intracellular RAF kinases (CRAF, BRAF) and cell surface kinase receptors (c-KIT, FLT-3, RET, 
VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β).
3,6
  Sorafenib is a potent inhibitor of Raf-1, a 
member of the RAF/MEK/ERK signaling pathway, a signaling cascade that ultimately modulates 
gene expression related to cellular proliferation and tumorigenesis.
6  
Sorafenib may additionally 
block the activation of EGFR.
5  
Common toxicities experienced by patients treated with sorafenib include diarrhea, hand-
foot skin reaction (HFSR), hypertension, and rash.
3
  These toxicities have the potential to limit 
the use of sorafenib in the oncology setting due to their unfavorable and consequent effects on 
patients’ adherence to treatment and requirements for sorafenib dose interruptions or reductions, 
both of which may reduce sorafenib’s antitumor efficacy due to the lack of therapeutic 
optimization.
7
  To our knowledge, no novel genetic biomarkers currently exist clinically to 
identify patients at risk of sorafenib-induced toxicity.  The purpose of this study was to identify, 
for the first time, genetic markers of sorafenib toxicity in order to optimize its efficacy and 
minimize its toxicity in mRCC patients treated with sorafenib. 
METHODS 
Patient Population 
The Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) Study is 
a randomized, placebo-controlled, double-blind phase 3 trial of sorafenib in advanced clear-cell 
RCC patients resistant to standard treatment, including cytokine-based, interleukin-2, and 
interferon therapies.
9
  Nine hundred and three individuals with mRCC were enrolled and 
randomized 1:1 to receive continuous treatment with oral sorafenib at a dose of 400 mg twice 
daily (N=451) or placebo (N=452).  The primary endpoint was overall survival (OS), and the 
secondary endpoint was progression free survival (PFS).  The safety analysis assessed and 
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graded toxicities based upon the Common Terminology Criteria for Adverse Events (CTCAE), 
version 3.0.
8
  The toxicities reported that were significantly higher in the sorafenib arm 
compared to the placebo arm (P<0.001) included: diarrhea, hand-foot skin reaction (HFSR), 
hypertension, rash or desquamation, alopecia, and pruritus.  Escudier et al. concluded that 
compared to placebo, treatment with sorafenib prolongs PFS in patients with advanced clear-cell 
renal cell carcinoma in whom previous immunotherapy has failed,
9 
 leading the way for the FDA 
approval of sorafenib for treatment in mRCC. 
Of the 903 individuals enrolled in the TARGET study, 295 individuals with usable DNA 
were included in the genotyped patient population for analysis.  Of the 295 individuals in the 
genotyped patient population, 153 individuals in the sorafenib arm were included.  All 153 
patients had progression-free survival (PFS) of greater than or equal to 29 days; a duration of 
sorafenib therapy of at least 29 days was assumed to be an adequate duration of exposure to the 
drug in order that reported toxicities could be considered to be drug-induced by sorafenib. 
Patient demographics and baseline characteristics are listed in Table 1. 
Statistical Analysis 
Using a candidate gene and candidate single nucleotide polymorphism (SNP) approach, 
genetic variants were selected to test associations between genotype and sorafenib-induced 
toxicities, which included diarrhea, HFSR, hypertension, and rash or desquamation.  The 
candidate genes to be genotyped were included based upon accumulated knowledge of sorafenib 
pharmacology and/or RCC pathogenesis. 
A set of SNPs within genes of interest were genotyped on the Illumina Golden Gate 
platform.  SNPs with minor allele frequency (MAF) < 0.01, Hardy-Weinberg equilibrium 
(HWE) exact P-value < 0.0001, and missingness < 0.025 were removed from the analysis, 
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leaving 1,116 SNPs.  SNPs within replicated samples that had inconsistent genotypes were 
removed, leaving a final set of 1,020 SNPs.  These data were used to impute genotypes within 
25kb of the transcription start and stop site of each gene using the Impute2 software package. 
 
Table 1. Demographic and baseline characteristics of genotyped patients (N=153) compared to 







Sex Male 114 (74.5%) 655 (72.5%) 
Age 
Median (years) 59 58.5 
Range (years) 19-80 19-86 
Race Caucasian 113 (73.9%) - 
ECOG Performance Status 
Grade 0 81 (52.9%) 429 (47.5%) 
Grade 1 72 (47.1%) 459 (50.8%) 
PFS 
Median (days) 127 - 
Range (days) 29-413 - 
Time since diagnosis 
Median (years) 1.65 2 
Range (years) 0.2-19.5 <1-20 
Previous interleukin-2 or 
Interferon 
Yes 139 (90.8%) 742 (82.2%) 
No 14 (9.2%) 161 (17.8%) 
Metastasis in liver or lung 
Yes 132 (86.3%) - 
No 21 (13.7%) - 
  ECOG: Eastern Cooperative Oncology Group; PFS: Progression-free survival 
 
 
A set of 19,282 genetic variants, both directly genotyped and imputed, were examined in 
153 patient samples with toxicity information.  SNPs with MAF < 0.05, HWE exact P-value < 
0.0001, and missingness < 0.05 were removed from the analysis, leading to a set of 5,846 
variants.  Linkage disequilibrium (LD) based pruning was performed on this data set in a 
pairwise manner using the following approach: a) consider a window of 50 SNPs, b) calculate 
LD between each pair of SNPs in the window, c) remove one of a pair of SNPs if the LD is 
greater than 0.5, d) shift the window five SNPs forward and repeat the procedure.  SNP pruning 
led to a final set of 685 SNPs for association testing. 
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A basic case/control association test was performed for each toxicity to examine 
genotype-phenotype associations, allowing for determination if exposure to sorafenib is 
associated with a toxicity outcome.  A chi-squared test was utilized to compare allele frequencies 
between cases (individuals who received sorafenib and experienced a toxicity of interest) and 
controls (individuals who received sorafenib and did not experience a toxicity of interest).  A 
Benjamini-Hochberg multiple testing correction was performed, and a corrected P-value 
threshold of 0.05 was used to determine significance.  All filtering and statistical analyses were 
performed using the PLINK software package. 
Data Collection 
Toxicity data of patients enrolled in the TARGET Study was provided by Bayer.  
Toxicities of Grades 2-4 based upon the CTCAE, version 3.0,
8
  reported for patients – including 
diarrhea, HFSR, hypertension, and rash or desquamation – were recorded.  Recorded toxicities 
were grouped by actual grade of event reported for each toxicity as well as grouped into 
composite categories of Grade ≥ 2 and Grade ≥ 3 events for each toxicity.  The highest grade 
event of each reported toxicity for each individual was included in the case/control association 
analysis; i.e. a patient who experienced both a Grade 2 event of diarrhea and a Grade 3 event of 
diarrhea was only included to have experienced one Grade 3 event of diarrhea.  Patients could 
experience multiple toxicity events of different classifications, and these events were recorded 
and included in the analysis; i.e. a patient who experienced one Grade 2 event of diarrhea and 
one Grade 3 event of HFSR was included to have experienced both of these toxicity events in 
their appropriate groupings.  Grade 2 toxicities were recorded and included in the analysis based 
upon sorafenib existing as an oral chemotherapy agent in which patients administer at home as 
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compared to intravenous chemotherapy agents, which require an outpatient clinic visit for 
administration and offer a stricter assessment of medication adherence. 
RESULTS 
Of the 153 genotyped patients, 28 patients (18 percent) experienced Grade ≥ 2 diarrhea, 
and 6 patients (4 percent) experienced Grade ≥ 3 diarrhea (Table 2). A comparison of the 
frequency of diarrhea in the sorafenib arms of the TARGET study and the genotyped patient 
population can be found in Table 2. 
 
Table 2. Comparison of frequency of diarrhea in sorafenib arms of TARGET study and 
genotyped patients 
  Grade 2 Grade 3 or 4 
  Cases Frequency Cases Frequency 
Cases of diarrhea in 
sorafenib arm, TARGET 
(N=451) 56 12.4% 11 2.4% 
Cases of diarrhea in 
sorafenib arm, genotyped 
(N=153) 
22 14.4% 6 3.9% 
Grade ≥ 2 Grade ≥ 3 
Cases Frequency Cases Frequency 
28 18.3% 6 3.9% 
 
 
The A allele of rs917881 (G>A), an intronic variant (17 percent allele frequency) in the 
epidermal growth factor receptor (EGFR) gene, was associated with an increased risk of Grade ≥ 
2 diarrhea (P=0.00006; P=0.04 after Bonferroni’s correction; odds ratio 3.6).  As depicted in 
Figure 1, an uptrend in the frequency of the A allele of rs917881 in sorafenib-treated patients 
existed with reported occurrence of diarrhea toxicity and as the grade of diarrhea increased. 
The GG genotype of rs917881 was more common in the total patient population 
(N=153); however, in the diarrhea subgroups, cases of Grade ≥ 2 diarrhea and Grade ≥ 3 diarrhea 
occurred in a higher percentage in sorafenib-treated patients with the AA genotype of rs917881 
as compared to the total patient population (Figure 2).  In addition, cases of Grade ≥ 2 diarrhea 
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and Grade ≥ 3 diarrhea occurred in a higher percentage in sorafenib-treated patients with the AG 
genotype of rs917881 as compared to the total patient population (Figure 2). 
 
 




Figure 2. Frequency of the EGFR AA, AG, and GG genotypes of rs917881 by grade of diarrhea 
 
 
The frequency of Grade ≥ 2 diarrhea was 50 percent (3/6) in patients with the AA 
genotype, 33 percent (15/45) in patients with the AG genotype, and 10 percent (10/102) in 
patients with the GG genotype (Table 3).  The frequency of Grade ≥ 2 diarrhea was 35 percent 
(18/51) in patients with the A allele (AA+AG) versus 10 percent (10/102) in patients with two G 
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alleles, the GG genotype, and the frequency of Grade 3 diarrhea was 8 percent (4/51) in patients 
with the A allele (AA+AG) versus 2 percent (2/102) in patients with the GG genotype (Table 3). 
 
Table 3. Cases and frequency of diarrhea based upon the rs917881 genotype of EGFR 





Total patients (N=153) 6 45 102 51 102 
    Cases of Grade ≥2 
diarrhea (N=28) 3  (50.0%) 15  (33.3%) 10  (9.8%) 18  (35.3%) 10  (9.8%) 
    Cases of Grade ≥3 
diarrhea (N=6) 1  (16.7%) 3  (6.7%) 2  (2.0%) 4  (7.8%) 2  (2.0%) 
 
 
The breakdown of the cases and frequency of diarrhea based upon the rs917881 genotype 
and each individual allele can be found in Table 3.  Nineteen patients experienced two or more 
toxicity events.  No other variants were significantly associated with sorafenib toxicity after 
Bonferroni correction. 
CONCLUSION 
To our knowledge, this is the first reported study of a genetic basis of sorafenib-induced 
toxicity.  Sorafenib was found to be associated with diarrhea toxicity that may limit its 
therapeutic use in some patients.  The SNP rs917881 (G>A), a common intronic variant in the 
EGFR gene, was associated with an increased risk of Grade ≥ 2 diarrhea in mRCC patients 
treated with sorafenib.  EGFR is expressed on cells of epithelial origin, including the 
gastrointestinal tract and the skin.
5
  Oral anti-EGFR tyrosine kinase inhibitors (TKIs) are known 
to be strongly associated with gastrointestinal toxicities including diarrhea.
5  
The 
pathophysiology of anti-EGFR-induced diarrhea is believed to result from excessive chloride 
secretion, which induces a secretory diarrhea, through dysregulated EGFR signaling to 




EGFR activates the RAF/MEK/ERK downstream signaling cascade, which is involved in 
the regulation of cell proliferation, survival, differentiation, and invasion and metastasis; EGFR 
is also frequently and aberrantly activated in cancer.
6,13
  This study generates the hypothesis that 
patients with the A allele of rs917881 who are treated with sorafenib may be at an increased 
susceptibility to Grade ≥ 2 diarrhea as a result of decreased EGFR expression, which may 
increase the diarrhea toxicity of sorafenib through potentiated inhibition of the RAF/MEK/ERK 
pathway.  Inhibition of RAF kinase, a critical component of the EGFR signaling pathway and 
known target of sorafenib
6
 (Figure 3), may result in downstream inhibitory effects on ERK 
activation, which regulates chloride channels on colonic epithelial cells, resulting in excessive 
chloride secretion and a subsequent secretory diarrhea (Figure 4). 
 
 




Alternative mechanisms for sorafenib-induced diarrhea should additionally be 
considered, as other hypotheses for diarrhea induced by TKI inhibitors are present in the 
literature.  For EGFR inhibitors, decreased EGFR signaling, which is expressed on epithelial 
cells of the gastrointestinal tract,
5 
may reduce growth and healing of the intestinal epithelium, 
leading to mucosal atrophy and diarrhea.  TKIs which are majorly cleared via the fecal route of 




to local irritation to the gut by the drug and its metabolites in the feces and to subsequent 
diarrhea.
10  
Furthermore, sorafenib is known to inhibit VEGFR;
3
 diarrhea induced by VEGFR 









Several limitations exist for the present study.  The reduced number of patients enrolled 
in the TARGET Study with usable DNA for genotypic analysis resulted in a small sample size 
for the present case/control association testing.  However, the genotyped patient population data 
was believed to be representative of the TARGET Study patient population, as evidenced by the 
similar baseline and demographic characteristics and reported diarrhea toxicity data of the two 
populations.  In addition, PFS was utilized as a surrogate marker for sorafenib exposure in the 
present analysis.  The lack of sorafenib exposure data available in relation to the date of 
occurrence of reported toxicities for TARGET patients treated with sorafenib led to assumptions 
having to be made regarding the appropriate adherence to sorafenib by patients and the certainty 
of reported toxicities being induced by sorafenib.  Furthermore, current evidence indicates that 
clinically relevant differences exist between the toxicity profiles of targeted therapies, including 
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between targeted drug agents that share the same major mechanism of action and between the 
toxicity profiles of a single targeted drug agent for different tumor types.
7
  This may make the 
findings of the present study non-generalizable to other targeted therapies which may inhibit 
EGFR.  Further large controlled studies are needed to validate the association between rs917881 
and sorafenib-induced diarrhea toxicity and to investigate other genetic variants and potential 
associations that may exist with treatment with sorafenib or other targeted agents. 
The associations of the genotypes of patients and drug-induced phenotypes can be 
utilized clinically in order to optimize patient care.
1  
The SNP rs917881 in the EGFR gene may 
make certain mRCC patients more susceptible to the diarrhea toxicity of sorafenib.  While 
diarrhea toxicity with sorafenib does not frequently require dose interruptions to therapy and can 
typically be treated with loperamide,
5,14 
dose reductions to target individual patients’ levels of 
tolerability that may be required for patients to safely continue therapy may negatively affect 
sorafenib’s antitumor efficacy due to the lack of therapeutic dose achievement.
9
  Identification of 
pharmacogenetic variants such as rs917881 that associate with sorafenib toxicity may impact 
clinician treatment and improve patient outcomes in regard to sorafenib efficacy due to enhanced 
tolerability to the drug and an improved adverse event profile.  Utilizing genetic variants to guide 
therapy can aid in accomplishing the goal of pharmacogenetics in understanding how genetic 
variants influence drug efficacy and toxicity and applying this knowledge to optimize the 
treatment of malignancies in order to improve survival and to mitigate toxicities.  Ongoing 
studies include replication analyses in additional sorafenib-treated patient cohorts, including 
CALGB 80802 (HCC patients), and functional studies in experimental models to assess the 
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